Disashi T, Iwaoka T, Inoue J, Naomi S, Fujimoto Y, Umeda T, Tomita K
Third Department of Internal Medicine, Kumamoto University School of Medicine, Japan.
Endocr J. 1996 Aug;43(4):397-402. doi: 10.1507/endocrj.43.397.
Changes in magnesium metabolism, along with those in sodium, were investigated in 17 patients with Graves' disease (14 females and 3 males, mean +/- SD, 44.8 +/- 12.2 years) and their relationship to plasma levels of thyroid hormones were assessed before and after treatment. Each patient was studied in hyperthyroid state and euthyroid state after treatment. Each patient was studied in hyperthyroid state and euthyroid state after treatment with methimazole. Treatment with methimazole increased the magnesium concentration both in erythrocytes (2.00 +/- 0.18 vs. 2.08 +/- 0.24 mmol/l cells, P < 0.05) and in serum (0.72 +/- 0.12 vs. 0.84 +/- 0.11 mmol/l, P < 0.001) but both urinary output and fractional excretion of magnesium decreased significantly (P < 0.05 and P < 0.001, respectively). The erythrocyte sodium concentration decreased with treatment (10.7 +/- 2.6 vs. 8.1 +/- 1.1 mmol/l cells, P < 0.001) but the serum sodium remained unchanged (140.9 +/- 1.9 vs. 140.9 +/- 2.1 mmol/l, NS). Urinary excretion of sodium also decreased with treatment (P < 0.05), but only changes in indices of magnesium metabolism (decrease in renal fractional excretion, rise in serum level) correlated significantly with those of the thyroid functions with treatment. These observations clearly indicate that in Graves' disease, the magnitude of magnesium metabolism alteration is closely related to the extent of the increase in thyroid hormones in plasma.
对17例格雷夫斯病患者（14例女性，3例男性，平均±标准差，44.8±12.2岁）的镁代谢变化以及钠代谢变化进行了研究，并评估了治疗前后它们与血浆甲状腺激素水平的关系。每位患者在甲亢状态和治疗后的甲状腺功能正常状态下均接受了研究。每位患者在接受甲巯咪唑治疗后的甲亢状态和甲状腺功能正常状态下均接受了研究。甲巯咪唑治疗使红细胞中的镁浓度（2.00±0.18 vs. 2.08±0.24 mmol/L细胞，P<0.05）和血清中的镁浓度（0.72±0.12 vs. 0.84±0.11 mmol/L，P<0.001）均升高，但尿量和镁的排泄分数均显著降低（分别为P<0.05和P<0.001）。红细胞钠浓度随治疗而降低（10.7±2.6 vs. 8.1±1.1 mmol/L细胞，P<0.001），但血清钠保持不变（140.9±1.9 vs. 140.9±2.1 mmol/L，无显著性差异）。钠的尿排泄也随治疗而降低（P<0.05），但只有镁代谢指标的变化（肾排泄分数降低，血清水平升高）与治疗后的甲状腺功能指标显著相关。这些观察结果清楚地表明，在格雷夫斯病中，镁代谢改变的程度与血浆中甲状腺激素增加的程度密切相关。
